2’-FL is the most abundant Human Milk Oligosaccharide (HMO) in breastmilk⁴
Infatrini Supports Catch Up Growth in Infants with Faltering Growth¹⁻³
Infatrini is a Food for Special Medical Purposes, designed to support the dietary management of disease-related malnutrition and growth failure in infants and young children.
With 25 years of trusted nutritional expertise‡, we are now excited to introduce our latest innovation - Infatrini with 2'-FL + scGOS / lcFOS prebiotics.
HMOs are integral in supporting the infant’s immune system⁵
Infatrini is the only† high energy formula for infants with 2'-FL + scGOS / lcFOS Prebiotics
Over 25 years of Infatrini & Clinical Research in Infants with Faltering Growth
Well-tolerated in infants with faltering growth6
Meets increased nutritional needs of infants with faltering growth1-3,6-9
Improved growth and clinical outcomes, even in the most critically ill children1-3
Provides immune support10-15, 16-24¥, 25^, 26^, 27*
The addition of 2’-FL to Infatrini compliments scGOS/lcFOS prebiotics to provide immune support10-15, 16-24¥, 25^, 26^, 27*
scGOS/lcFOS (9:1)
GOS/FOS stimulates growth of beneficial bacteria10
Prebiotic effect10-15
Stimulate growth and activity of beneficial bacteria
2'-FL
Inhibits pathogen adhesion16-18¥
Blocking the route of infection19, 20¥
2'-FL blocks entry of pathogens
scGOS/lcFOS (9:1) & 2'-FL
Direct effect in immune cells21-24^
Direct immunomodulatory effects at the cellular level (e.g. modulating dendritic cell maturation)
IMPORTANT NOTICE:
Infatrini is a Food for Special Medical Purposes for the dietary management of disease-related malnutrition and growth failure in infants and young children. It must be used under medical supervision. Suitable as a sole source of nutrition for infants from birth and young children up to 18 months of age (or 9kg). Refer to label for details.
2’-FL: 2'-Fucosyllactose
scGOS/ lcFOS: short chain galacto-oligosaccharides / long chain fructo-oligosaccharides
† MIMS UK & Ireland, May 2025.
‡ Infatrini was launched in 1999 (data on file).
¥ preclinical data;
^ study in healthy term infants recieving a formula with GOS only (control) or GOS plus either 0.2g/L or 1.0g/L 2'-FL and compared to a breastfed reference group;
*post hoc analysis of the control group and the 0.2g/L 2'-FL formula group from the Marriage et al. 2015 study.
– Product can be provided to patients upon the request of a Healthcare Professional. They are intended for the purpose of professional evaluation only.
- Scheeffer VA et al. 2020. JPEN.44(2):348-354.
- Eveleens RD et al. 2019. J Hum Nutr Diet. 32:3-10.
- Zhang H et al. 2019 Nurs Crit Care. 24(2):97-102
- Thurl S et al. Nutrition Reviews. 2017. 75(11);920–933
- Ayechu-Muruzabal V et al. 2018. Front Pediatr. 6:239.
- Delsoglio M et al. JPGN Reports. 2024; 5(S1):S1207
- EFSA 2014
- Cui Y et al. 2018. J Parenter Enteral Nutr. 42:196-204.
- Hawkes JS et al. 2006. Eur J Clin Nutr. 60(2):254–264
- Knol J et al. Acta Paediatrica 2005. 94(S449);31-33.
- Moro G et al. J Pediatr Gastroenterol Nutr. 2002;34:291-5.
- Moro G et al. Arch Dis Child. 2006;91:814-9.
- Knol J et al. J Pediatr Gastroenterol Nutr 2003. 36;566
- Bruzzese E et al. J Pediatr Gastroenterol Nutr 2006. 42;E1-E11
- Arslanoglu S et al. J Nutr 2008. 138:1091-1095
- Ruiz-Palacios GM et al. J Biol Chem. 2003;278(16):14112-20.
- Yu ZT et al. J Nutr. 2016;146(10):1980-1990.
- Weichert S et al. Nutr Res. 2013;33(10):831-8.
- Newburg DS et al. Glycobiolo y. 2004 Mar;14(3):253-63.
- Morrow A et al. J Nutr. 2005 May;135(5):13047.
- Overbeek S et al. J Pediatr Gastroenterol Nutr. 2019;68(S1):N-O-008
- Vos AP et al. Int Immunopharmacol. 2006;6(8):1277-86.
- Xiao L et al. Immune Re ulation in Mice. J Nutr. 2019b;149(5):856-69.
- van den Elsen LWJ et al. Benef Microbes. 2019;10(3):279-291.
- Goehrin KC et al. J Nutr. 2016;146(12):2559–2566.
- Marria e BJ et al. J Pediatr Gastroenterol Nutr. 2015;61(6):649-58.
- Reverri EJ et al. Nutrients. 2018;10(10):1346.
Accurate at the time of publication: May 2025.